Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model

Neuroscience Letters

Volumn 283, Issue 3, 2000, Pages 233-235

  Guidetti, Paolo ^a   Hemachandra Reddy, P ^b   Tagle, Danilo A ^b   Schwarcz, Robert ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

3 Hydroxykynurenine; Excitotoxicity; Free radicals; Huntingtin; Kynurenic acid; Neurodegeneration

Indexed keywords

3 HYDROXYKYNURENINE; KYNURENIC ACID; KYNURENINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MOUSE; NEOSTRIATUM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; TRANSGENIC ANIMAL;

EID: 0034647059     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)00956-3     Document Type: Article

References (24)

1. Aronin N., Kim M., Laforet G., DiFiglia M. Are there multiple pathways in the pathogenesis of Huntington's disease? Phil. Soc. Trans. R. Soc. Lond. B. 354:1999;995-1003.
2. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
3. Beal M.F., Matson W.R., Storey E., Milbury P., Ryan E.A., Ogawa T., Bird E.D. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 108:1992;80-87.
4. Connick J.H., Carlà V., Moroni F., Stone T.W. Increase in kynurenic acid in Huntington's disease motor cortex. J. Neurochem. 52:1989;985-987.
5. Cozzi A., Carpenedo R., Moroni F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab. 19:1999;771-777.
6. Eastman C.L., Guilarte T.R. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res. 15:1990;1101-1107.
7. Espey M.G., Chernyshev O.N., Reinhard J.F. Jr., Namboodiri M.A.A., Colton C.A. Activated human microglia produce the excitotoxin quinolinic acid. NeuroReport. 8:1997;431-434.
8. Foster A.C., Vezzani A., French E.D., Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48:1984;273-280.
9. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56:1991;2007-2017.
10. Guidetti P., Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11:1999;3857-3863.
11. Harris C.A., Miranda A.F., Tanguay J.J., Boegman R.J., Beninger R.J., Jhamandas K. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br. J. Pharmacol. 124:1998;391-399.
12. Heyes M.P., Quearry B.J. Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. J. Chromatogr. 428:1988;340-344.
13. Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., Markey S.P. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320:1996;595-597.
14. Pearson S.J., Reynolds G.P. Increased brain concentration of a neurotoxin 3-hydroxykynurenine, in Huntington's disease. Neurosci. Lett. 144:1992;199-201.
15. Reddy P.H., Charles V., Williams M., Miller G., Whetsell W.O. Jr., Tagle D.A. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Phil. Trans. R. Soc. Lond. B. 354:1999;1035-1045.
16. Reynolds G.P., Pearson S.J., Halket J., Sandler M. Brain quinolinic acid in Huntington's disease. J. Neurochem. 50:1988;1959-1960.
17. Saito K., Markey S.P., Heyes M.P. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience. 31:1992;25-39.
18. Sapp E., Kegel K.B., Aronin N., Tohyama K., Uchiyama Y., Bhide P., VonSattel J.P., DiFiglia M. Microglia accumulate in the HD striatum and cortex. Soc. Neurosci. Abstr. 25:1999;334.5.
19. Schwarcz R., Whetsell W.O. Jr., Mangano R.M. Quinolinic acid, an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 219:1983;316-318.
20. Schwarcz R., Okuno E., White R.J., Bird E.D., Whetsell W.O. Jr. 3-Hydroxyanthranilic acid oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natl. Acad. Sci. USA. 85:1988;4079-4081.
21. Schwarcz R., Guidetti P., Roberts R.C. Quinolinic acid and kynurenic acid: glia-derived modulators of excitotoxic brain injury. Aschner M., Kimelberg H.K. The Role of Glia in Neurotoxicity. 1996;245-262 CRC Press, Boca Rotan.
22. Speciale C., Cini M., Wu H.-Q., Salvati P., Schwarcz R., Molinari A., Calabresi M., Varasi M. Kynurenic acid-enhancing and anti-ischemic effects of the potent kynurenine 3-hydroxylase inhibitor FCE 28833 in rodents. Adv. Exp. Med. Biol. 398:1996;221-227.
23. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45:1993;309-379.
24. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Jr. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44:1985;559-577.